

### ABOUT THE JOURNAL SCOPE

*Clinical and Translational Science (CTS)*, an official journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Translational medicine is a multi-faceted discipline with a focus on translational therapeutics. In a broad sense, translational medicine bridges across the discovery, development, regulation, and utilization spectrum. Research may appear as Full Articles, Brief Reports, Commentaries, Phase Forwards (clinical trials), Reviews, or Tutorials. *CTS* also includes invited didactic content that covers the connections between clinical pharmacology and translational medicine. These additional features provide context for research articles and facilitate understanding for a wide array of individuals interested in clinical and translational science. *CTS* welcomes high quality, scientifically sound, original manuscripts focused on clinical pharmacology and translational science, including animal, *in vitro*, *in silico*, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of both traditional drugs and innovative modalities.

Topics of interest include:

- Translational medicine, including studies focused on Interrogation/evaluation of mechanism-of-action, human physiology, and interruption of disease pathophysiology
- Hypothesis generating non-clinical and clinical studies, including small clinical trials
- Clinical pharmacology studies with a focus on translational research in discovery, development, regulation and use of pharmacologic agents to improve clinical outcome, and inform optimal use of therapeutics in patients
- Evaluation of various biomarkers as well as assessing the linkage between biomarker response and clinical endpoints in patients, including studies that identify or support biomarkers that can be used at any stage of drug development
- Studies of response to a therapeutic intervention in a particular disease that may translate to a response in another disease, as well as translation of safety signals across species and/or patient populations
- The science and practice of translational medicine, including topics such as models of human disease and their therapeutic implications as well as practical aspects like improvements to study design or conduct and translational medicine methods.
- Studies that guide Phase 2 dose selection
- Studies that demonstrate effective translation between basic and clinical science
- Precision medicine
- Genomic medicine, including pharmacogenomics, next generation sequencing, pharmacometabolomics, and functional genomics
- Electronic and mobile health applications as well as wearables
- Regulatory and public health policy implications of translational studies
- Quantitative and systems pharmacology, PK/PD model-based and mechanistic understanding of disease biology and pharmacology, as these relate to translational medicine

*CTS* is an official journal of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).

ISSN 2163-8306

URL <http://cts.msubmit.net>

### ABSTRACTING

This journal is covered by: Academic Search (EBSCO Publishing), Academic Search Alumni Edition (EBSCO Publishing), Biological Abstracts (Thomson Reuters), BIOSIS Previews (Thomson Reuters), Biotechnology & Bioengineering Abstracts (ProQuest), CSA Biological Sciences Database (ProQuest), Embase (Elsevier), MEDLINE/PubMed (NLM), Science Citation Index

Expanded (Thomson Reuters), SCOPUS (Elsevier), and Web of Science (Thomson Reuters).

### EDITORIAL PROCESS

#### Criteria for Publication

The principal criteria for publication of papers in *CTS* are that they:

- Report original scientific research (the main results and conclusions must not have been published or submitted elsewhere)
- Are of outstanding scientific importance
- Reach a conclusion of interest to an interdisciplinary readership

#### Selection Process of Submitted Papers

Upon submission, the manuscript is assigned to an Associate Editor covering the subject area, who makes the initial decision on whether to send it out for peer-review. The journal receives many more high-quality submissions than it can publish and the Associate Editors strive to identify maximally impactful papers. Papers not chosen for peer-review are quickly returned to the authors to minimize unproductive delays and allow sufficient time to prepare the manuscript for submission to another journal.

If selected for peer review, referees are chosen by the Associate Editor based upon subject expertise and ability to evaluate the paper fully and fairly, and in a timely manner. The ideal referee report indicates who will be interested in the new results and why, and will be used by the Associate Editor to help determine the impactfulness of publication in *CTS*. If a paper is selected for further consideration, authors are required to address the comments of the referees in a revised version of the paper.

The Associate Editor assigned to the paper is responsible for making a decision recommendation in light of the referees' reports. All recommendations are then considered by the Editor-in-Chief, who determines the final disposition for all papers.

### OPEN ACCESS PUBLICATION

All articles selected for acceptance in *CTS* will be published open access. Articles will be made freely available immediately upon publication. For accepted papers, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

The following license agreements are available:

Creative Commons Attribution Non-Commercial (CC-BY-NC) license

Creative Commons Attribution-Non-Commercial-NoDerivs (CC-BY-NC-ND) license.

From April 1, 2013, RCUK or Wellcome trust funded authors will be directed to sign the open access agreement under the terms of the Creative Commons Attribution (CC-BY) license in order to be funder compliant.

For more information on the terms and conditions of these licenses, please visit: <http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html>

Authors are required to pay an article processing fee per accepted article. The article processing charge is \$3,000/£2,000/€2,500 (plus VAT where applicable) for papers published under the Creative Commons Attribution Non-Commercial (CC-BY-NC) and the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License (CC BY-NC-ND). ASCPT members and dual ASCPT-ISO members will receive a reduced Article Processing Charge. The Article Processing Charge can be paid via credit card or by requesting that an invoice be issued. By paying this Article Processing Charge, authors are permitted to post the final, published PDF of their article on a website, institutional repository, or other free public server immediately upon publication.

### PREPARATION OF MANUSCRIPTS

#### CONTENT TYPES

**Author Submissions** (1) Article, (2) Review, (3) Phase Forward, (4) Commentary, (5) Book Review, (6) Letter to the Editor, (7) Tutorial, (8) Brief Report Submissions that do not adhere to the guidelines provided in this document will be returned to the author prior to consideration. Material that cannot fit within the allowed limit may be submitted as supplementary information.

#### (1) Article

**Word Limit:** 4,000 words excluding abstract, references, tables, and figures

**Abstract:** 150 words maximum

**References:** 50 maximum

**Figures/Tables:** 7 maximum

**Substantial novel research**

#### (2) Review

**Word Limit:** 4,000-8,000 words excluding introduction, references, tables, and figures

**Abstract:** no abstract for this article type; should include a 75-word Introduction

**References:** 75-100 maximum

**Figures/Tables:** 8 maximum

**High-quality, timely reviews covering important topics in the entire field of translational medicine**

#### (3) Phase Forward

**Word Limit:** 5,000 words excluding abstract, references, tables, and figures

**Abstract:** 150 words maximum

**References:** 60 maximum

**Figures/Tables:** 8 maximum

**Manuscripts developed from well-conducted, well reported, and relevant clinical trials with a particular focus on first-in-human, first-in-patient, and proof-of-concept.**

#### (4) Commentary

**Word Limit:** 1,600 words excluding introduction, references, tables, and figures

**Abstract:** no abstract for this article type; should include a 75-word Introduction

**References:** 10 maximum

**Figures/Tables:** 2 maximum

**Typically highlights findings of a paper in the same issue, presented in a wider scientific and clinical context**

#### (5) Book Review

**Word Limit:** 700 words

**Abstract:** no abstract for this article type

**References:** no references for this article type

**Figures/Tables:** Cover image will be secured prior to publication by the Editorial Office

#### (6) Letter to the Editor

**Word Limit:** 400 words excluding references, tables, and figures

**Abstract:** no abstract for this article type

**References:** 5 maximum

**Figures/Tables:** 1 maximum

**Letters must be submitted within 6 months of publication of the subject article. A Letter to the Editor must reference the original source, and a Response to Letter must reference the Letter to the Editor in the first few paragraphs. Letters to the Editor can use an arbitrary title, but a Response must cite the title of the Letter: e.g., Response to [title of Letter]**

#### (7) Tutorial

**Word Limit:** 4,000-8,000 excluding introduction, references, tables, and figures

**Abstract:** no abstract for this article type; should include a 75-word introduction

**References:** 75-100 maximum

**Figures/Tables:** 8 maximum

**Educational article providing practical tutorial on tools, methodologies and approaches in translational medicine.**

### (8) Brief Report

**Word Limit:** 2,000 excluding abstract, references, tables, and figures. Results and Discussion sections may be combined.

**Abstract:** 150 words maximum

**References:** 25 maximum

**Figures/Tables:** 2 maximum

*Brief Reports are intended as short and complete reports of novel research findings of high importance to the field. Reports of preliminary experiments are unacceptable. Brief reports should be especially significant and timely and reach a clear conclusion.*

### FORMAT OF MANUSCRIPTS

**General format** Manuscripts must be typed in English and be in a single column, double-spaced format. All manuscript pages must be numbered. Manuscript text files must be in MS Word or LaTeX format.

**Title page** This should include (a) the complete manuscript title; (b) all authors' names and affiliations; and (c) the name and address for correspondence, fax number, telephone number, and e-mail address. The title page should also include the number of figures and tables and the key words.

**Title** Manuscript titles should be no more than 150 characters and spaces. Running titles should be no more than 50 characters and spaces.

**Text** Articles should consist of the following ordered sections:

Title Page

Abstract

Introduction

Methods (must contain IRB or IACUC approval: see **Informed Consent and Ethics** below)

Results

Discussion

Study Highlights

Acknowledgements

Conflict of Interest/Disclosure

Author Contributions

References

Figure Legends

**Originality** A submitted manuscript must be an original contribution not previously published (except as an abstract), must not be under consideration for publication elsewhere, and, if accepted, must not be reproduced elsewhere without the consent of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Although the editors, editorial board, and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with *Clinical and Translational Science*, its editors, ASCPT, or Wiley.

**Conflict of Interest** *CTS* subscribes to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. These principles require that participants in the peer review and publication process disclose all relationships that could be viewed as presenting a potential conflict of interest. Disclosures must include employment, consultancies, honoraria, stock ownership, stock options, expert testimony, grants received and pending, patents received and pending, royalties, and in-kind contributions. Editors may publish disclosed information if they believe readers will find it important in judging the manuscript. Institutional and personal conflicts of interest must also be declared.

**Informed Consent and Ethics** *CTS* adheres to the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals* established by the International Committee of Medical Journal Editors. A full description of recommendations can be found at <http://www.icmje.org>. Research projects involving human subjects require review and approval by an Institutional Review Board (IRB). When reporting experiments on human subjects, indicate whether the procedures were in accordance with the ethical standards of the responsible committee

on human experimentation or with the Helsinki Declaration of 1975 (as revised in 1983). IRB or IACUC approval must be cited in the Methods section of the text. If there has been no IRB review of the study, please indicate so in the cover letter. In such situations, the manuscript will be reviewed to determine if IRB review should have been conducted. The result of this review may determine whether or not the manuscript will be considered for publication.

**Statement of Human and Animal Rights** When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

**Clinical Trials Registry** Registration in a public trials registry is required for publication in *CTS*. A clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, including exploring pharmacokinetics or safety and tolerability (e.g., phase 1 trials) are exempt. Registration must be with a registry that meets the following criteria: (1) accessible to the public at no charge; (2) searchable by electronic methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed), and funding source(s). Examples of registries that meet these criteria include (1) The registry sponsored by the United States National Library of Medicine (<http://www.clinicaltrials.gov>); (2) The International Standard Randomised Controlled Trial Number Registry (<http://www.controlled-trials.com>); (3) The Cochrane Renal Group Registry (<http://www.cochrane-renal.org/trials/submitform.php>); (4) The National (United Kingdom) Research Register (<http://www.update-software.com/national/>); and (5) European Clinical Trials Database (<http://eudract.emea.eu.int/>).

**Abbreviations** Abbreviations should be defined at the first mention in the text and in each table and figure. Write out the full term for each abbreviation at its first use unless it is a standard unit of measure. For a list of standard abbreviations, please consult the CSE Manual for Authors, Editors, and Publishers (available from the Council of Science Editors, 12100 Sunset Hills Road, Suite 130, Reston, VA 20190) or other standard sources.

**Style** *The American Medical Association Manual of Style* (9th edition), *Stedman's Medical Dictionary* (27th edition) and *Merriam-Webster's Collegiate Dictionary* (10th edition) should be used as standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical name, and do not abbreviate them (a proprietary name may be given only with the first use of the generic name). Code names should be used only when a generic name is not yet available (the chemical name and a figure giving the chemical structure of the drug is required). Copyright or trade names of drugs should be capitalized and placed in parentheses after the name of the drug. Names and locations (city and state in United States; city and country outside

United States) of manufacturers of drugs, supplies, or equipment cited in a manuscript are required to comply with trademark law and should be provided in parentheses.

**Language Editing** Authors who require editing for language are encouraged to consult language editing services prior to submission.

### STUDY HIGHLIGHTS

Original research articles should include a Study Highlights section after the Discussion section in the manuscript text. The highlights section should include and answer each of the questions below. The entire section, not including the questions, should be under 150 words.

- What is the current knowledge on the topic?
- What question did this study address?
- What this study adds to our knowledge
- How this might change clinical pharmacology or translational science

### AUTHOR RESPONSIBILITY

Upon submission, the corresponding author must confirm full access to all data in the study and final responsibility.

### AUTHOR CONTRIBUTIONS

A list of each authors' contributions should be provided in the manuscript text. The standard contributions include: Wrote Manuscript, Designed Research, Performed Research, Analyzed Data, and Contributed New Reagents/Analytical Tools.

### ACKNOWLEDGMENTS

This should include sources of support, including federal and industry support. All authors who have contributed to the manuscript must be acknowledged. Medical writers, proofreaders, and editors should not be designated as full authors, but acknowledged here.

### DISCLOSURE

At the time of submission, each author must disclose and describe any involvement, financial or otherwise, that might potentially bias his or her work. Disclosures must be included in the text of the manuscript and the online submission form.

### REFERENCES

The reference list should contain the references in the order in which they are cited in the text (Vancouver style). Citations included in tables/figures count toward the maximum references allowed for the article type and must be included in the reference list. Tables created solely of references are not permitted. Only published works, as well as manuscripts in press, should be included in the reference list; articles that are submitted or in preparation should be referred to as "unpublished data" in the text. For publications in the reference list, all authors should be included unless there are more than 6, in which case only the first author should be listed followed by 'et al.' Titles of cited articles are required for all article types. For book citations, the publisher and city of publication are required; include the country (and state for US) for lesser-known cities or where any ambiguity is possible. Please note the following examples:

*Journal articles:*

Kashuba, A.D. et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. *Clin. Pharmacol. Ther.* **64**, 257–268 (1998).

*Books:*

Eisen, H.N. *Immunology: An Introduction to Molecular and Cellular Principles of the Immune Response* 5th edn. (Harper & Row, New York, 1974).

*Articles in books:*

Weinstein, L. & Schwartz, M.N. Pathogenic properties of invading microorganisms. In *Pathologic Physiology: Mechanisms of Disease* (eds. Sodeman, W.A., Jr. & Sodeman, W.A.) 457–473 (W.B. Saunders, Philadelphia, 1974).

### Website:

Fleischbein, J. Northeast Pacific long-term observation program. US GLOBEC <<http://globec.oce.orst.edu/groups/nep/index.html>> (2003). Accessed 13 April 2006.

### GUIDELINES FOR FIGURES AND ARTWORK

Detailed guidelines for submitting figures and artwork can be found at: [http://authorservices.wiley.com/prep\\_illust.asp](http://authorservices.wiley.com/prep_illust.asp). Using the guidelines, please submit production quality artwork at submission. Accepted figure files include PDF, TIFF, and EPS in PC format, preferably from Photoshop or Illustrator software. We can also accept Freehand 8, Canvas and CorelDraw (version 8 and above), but these files must be converted to postscript (EPS) format. For any figures submitted in Photoshop or TIFF format, we require layered files to be sent whereby all text, arrows or additional attributes are placed in individual layers within the file.

#### For single images:

**Width** 500 pixels (authors should select “constrain proportions,” or equivalent instructions, to allow the application to set the correct proportions automatically)

**Resolution** 125 dpi (dots per inch)

**Format** TIFF for photographs, EPS for line drawings or charts

**File naming** Please save image with .tiff or .eps extension to ensure it can be read by all platforms and graphics packages

#### For multi-part images:

**Width** 900 pixels (authors should select “constrain proportions,” or equivalent instructions, to allow the application to set the correct proportions automatically)

**Resolution** 125 dpi (dots per inch)

**Format** TIFF for photographs, EPS for line drawings or charts

**File naming** Please save image with .tiff or .eps extension to ensure it can be read by all platforms and graphics packages

### FIGURES

Figures should be numbered consecutively in the order of first citation in the text. If a table, figure or any other previously published material is included, the authors must obtain written permission to reproduce the material from the copyright owner and submit it with the manuscript. The original source should be cited. Figures and tables must be uploaded separately from the manuscript text. Each figure must be provided as an individual file. Composite figures should be submitted preassembled. Authors are encouraged to use color in their figures.

### FIGURE LEGENDS

Legends should be brief and specific and should appear after the Reference section in the manuscript text.

### TABLES

Accepted file types include MS Word. If you submit a LaTeX file, please provide a PDF copy as reference for the editorial staff. This PDF copy can be uploaded as a supplementary information file. Tables should be numbered consecutively in the order of first citation in the text. Supply a brief title for each table but place explanatory matter in the footnotes (not in the heading). Do not use internal horizontal and vertical lines. Tables and figures must be uploaded separately from the manuscript text. Please do not include multipart tables (such as Table 1a and 1b). Tables should be editable and not embedded images or excel files.

### JOURNAL STYLE

Papers should be prepared as follows:

1. See the artwork guidelines above
2. Do not make rules thinner than 1 pt (0.36mm)
3. Use a coarse hatching pattern rather than shading for tints in graphs
4. Color should be distinct when used as an identifying tool

5. Commas should be used to separate thousands

6. At first mention of a manufacturer, the town (state if USA) and country should be provided

### FILE FORMATS & REQUIREMENTS

Authors are required to submit final, publication-ready files at the revision stage, along with a version tracking all changes to the paper. Use the Track Changes mode in MS Word or indicate the revised text with bold, highlighted, or colored type. Authors should submit a point-by-point response to each referees' set of comments.

### SUPPLEMENTARY INFORMATION

Supplementary information is peer-reviewed material directly relevant to the conclusion of an article that cannot be included in the printed version owing to space or format constraints. It is posted on the journal's website and linked to the article online; it may include data files, graphics, movies, or extensive tables. The printed article must be complete and self-explanatory without the supplementary information.

**Supplying Supplementary Information Files** Authors should ensure that supplementary information is supplied in its FINAL format at submission, as it is not copy edited and will appear online exactly as submitted. It cannot be altered, nor new supplementary information added, after the paper has been accepted for publication. Please supply the supplementary information via the electronic manuscript submission system in an acceptable file format. Each supplementary figure must be provided as an individual high-resolution PDF, TIFF, or EPS file. Each supplementary table must be provided as an individual MS Word or Excel. Supplementary text must be provided in MS Word or Excel format. The number of supplementary information files should be limited to eight, and the total file size should not exceed 8 MB. Individual files should not exceed 1 MB.

**Accepted File Formats** File sizes must be as small as possible to expedite downloading. Images should not exceed 640 x 480 pixels. Movie files can be in Quick Time (.mov), or MPEG (.mpg) format. For movies, we recommend 480 x 360 pixels as the maximum frame size and a frame rate of 15 frames per second. If applicable to the presentation of the information, use a 256-color palette. Please consider the use of lower specification for all of these points if the supplementary information can still be represented clearly. Our recommended maximum data rate is 150 KB/s. Questions about the submission or preparation of supplementary information should be directed to the editorial office.

### EDITORIAL POLICIES PLAGIARISM

Plagiarism is when an author attempts to represent someone else's work as his or her own. Duplicate publication, sometimes called self-plagiarism, occurs when an author reuses substantial parts of his or her own published work without providing the appropriate references. This can range from getting an identical paper published in multiple journals, to 'salami-slicing,' where authors add small amounts of new data to a previous paper. Plagiarism can be said to have clearly occurred when large chunks of text have been cut-and-pasted. Such manuscripts would not be considered for publication in *CTS*. But minor plagiarism without dishonest intent is relatively frequent, for example, when an author reuses parts of an introduction from an earlier paper. The journal editors judge any case of which they become aware (either by their own knowledge of and reading about the literature, or when alerted by referees) on its own merits. If a case of plagiarism comes to light after a paper is published, the journal will conduct a preliminary investigation. If plagiarism is found, the journal will contact the author's institute and funding agencies. A determination of misconduct will lead the journal to run a statement, bidirectionally linked online to and from the original paper, to note the plagiarism and to provide a reference

to the plagiarized material. The paper containing the plagiarism will also be obviously marked on each page of the PDF. Depending on the extent of the plagiarism, the paper may also be formally retracted.

### IMAGE INTEGRITY AND STANDARDS

Images submitted with a manuscript for review should be minimally processed (for instance, to add arrows to a micrograph). Authors should retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data are unavailable, manuscript evaluation may be stalled until the issue is resolved. A certain degree of image processing is acceptable for publication (and for some experiments, fields and techniques is unavoidable), but the final image must correctly represent the original data and conform to community standards. The guidelines below will aid in accurate data presentation at the image processing level; authors must also take care to exercise prudence during data acquisition, where misrepresentation must equally be avoided. Authors should list all image acquisition tools and image processing software packages used. Authors should document key image gathering settings and processing manipulations in the Methods. Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. If juxtaposing images is essential, the borders should be clearly demarcated in the figure and described in the legend. The use of touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, is to be avoided. Processing (such as changing brightness and contrast) is appropriate only when it is applied equally across the entire image and is applied equally to controls. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (for example, through the use of a biased choice of threshold settings), is inappropriate, as is emphasizing experimental data relative to the control. When submitting revised final figures, authors may be asked to submit original, unprocessed images.

### CONFIDENTIALITY

*CTS* editors and editorial staff keep confidential all details about a submitted manuscript and do not comment to any outside organization about manuscripts under consideration by the journal while they are under consideration or if they are rejected. The journal editors may comment publicly on published material, but their comments are restricted to the content itself. After a manuscript is submitted, correspondence with the journal, referees' reports and other confidential material, whether or not the submission is eventually published, must not be posted on any website or otherwise publicized without prior permission from the editors. The editors themselves are not allowed to discuss manuscripts with third parties or to reveal information about correspondence and other interactions with authors and referees. Referees agree to maintain confidentiality of all manuscripts under consideration.

### COMMUNICATION WITH THE MEDIA

Authors must not discuss contributions with the media (including other scientific journals) until the publication date. The only exception is in the week before publication, during which contributions may be discussed with the media if authors and their representatives (institutions, funders) clearly indicate to journalists that their contents must not be publicized until the journal's press embargo has elapsed. Authors will be informed of embargo dates and timings after acceptance for publication of their articles. We reserve the right to halt the consideration or publication of a paper if this condition is broken. From time to time *CTS* will distribute to a registered list a press release summarizing selected content. Journalists are encouraged to read the full version of any papers they wish to cover, and are given the names of corresponding authors, together with phone

and fax numbers and email addresses. They receive access to the full text of papers about a week before publication on a password-protected website. The content of the press release and papers is embargoed until the time and date clearly stated on the press release. Authors may therefore receive calls or emails from the media during this time; we encourage them to cooperate with journalists so that media coverage of their work is accurate and balanced. Authors may also arrange their own publicity (for instance through their institutional press offices), but they must strictly adhere to our press embargo.

### COMMUNICATION BETWEEN SCIENTISTS

CTS does not wish to hinder communication between scientists. For that reason, different embargo guidelines apply to work that has been discussed at a conference or displayed on a preprint server and picked up by the media as a result. (Neither conference presentations nor posting on recognized preprint servers constitute prior publication.)

### CORRECTION AND RETRACTION POLICY

We recognize our responsibility to correct errors that we have previously published. Our policy is to consider refutations (readers' criticisms) of primary research papers, and to publish them online (in concise form) if and only if the author provides compelling evidence that a major claim of the original paper was incorrect. Corrections are published for significant errors at the discretion of the editors. Readers who have identified such an error should send an email to the editorial office of the journal, clearly stating the publication reference, title, author, and section of the article, and briefly explaining the error.

### CORRECTIONS TO THE PRINT AND ONLINE VERSIONS OF PEER-REVIEWED CONTENT

Publishable amendments requested by the authors of the publication are represented by an online notice in the journal because they affect the publication record and/or the scientific accuracy of published information. Where these amendments concern peer-reviewed material, they fall into one of four categories: erratum, corrigendum, retraction, or addendum, described here.

**Erratum** Notification of an important error made by the journal that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.

**Corrigendum** Notification of an important error made by the author(s) that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal. All authors must sign corrigenda submitted for publication. In cases where coauthors disagree, the editors will take advice from independent peer-reviewers and impose the appropriate amendment, noting the dissenting author(s) in the text of the published version.

**Retraction** Notification of invalid results. All coauthors must sign a retraction specifying the error and stating briefly how the conclusions are affected, and submit it for publication. In cases where coauthors disagree, the editors will seek advice from independent peer reviewers and impose the type of amendment that seems most appropriate, noting the dissenting author(s) in the text of the published version.

**Addendum** Notification of a peer-reviewed addition of information to a paper, usually in response to readers' request for clarification. Addenda are published only rarely and only when the editors decide that the addendum is crucial to the reader's understanding of a significant part of the published contribution.

### SUBMISSION AND PUBLICATION

#### SUBMISSION OF PAPERS

Manuscripts must be submitted online at <http://cts.msubmit.net>. Manuscripts are assessed by an Associate Editor upon submission. Only manuscripts that meet our editorial criteria are sent out for formal review. One compelling, negative review may be sufficient for a decision to reject.

#### COPYRIGHT

CTS utilizes a the Creative Commons Attribution-

Noncommercial-No Derivative Works 3.0 Unported License. The Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License allows readers to download the article and share it with others as long as they mention the author and link back to the original article. The article cannot be changed in any way or used commercially. For all accepted articles, the author identified as the formal corresponding author will receive an email prompting them to login into Author Services; where, via the Wiley Author Licensing Service (WALS), they will be able to complete the license agreement on behalf of all authors of the article. Failure to do so will result in delays to the publication of your paper.

**Offprints** may be ordered using the online order form available at <https://caesar.sheridan.com/reprints/redirect.php?pub=10089>.

#### PROOFS

An email will be sent to the corresponding author with a URL link from where proofs can be accessed and corrections submitted. Proofs must be returned within 48 hours of receipt. Failure to do so may result in a delay to publication. Extensive corrections cannot be made at this stage.

#### CONTACT INFORMATION

##### EDITORIAL

All business regarding manuscripts and peer review should be addressed to:

*Clinical and Translational Science*

528 North Washington Street

Alexandria, VA 22314

USA

Tel: +1.703.836.6981

Fax: +1.703.836.6996

Attn: [cts@ascpt.org](mailto:cts@ascpt.org), Managing Editor

[cts2@ascpt.org](mailto:cts2@ascpt.org), Senior Editorial Coordinator

##### BUSINESS MATTERS

All business correspondence and inquiries should be addressed to:

111 River Street

Hoboken, NJ 07030

USA

Tel: +201-748-6000